Novavax has released the study results for the phase-1 of the coronavirus vaccine that is being manufactured by the company. Novavax trials, carried out on 131 volunteers, showed that after 2 doses of the vaccine, participants developed neutralising antibodies at levels more than four times higher on average than the antibodies developed by people who had recovered from COVID-19.
Novavax has released the study results for the phase-1 of the coronavirus vaccine that is being manufactured by the company. Novavax trials, carried out on 131 volunteers, showed that after 2 doses of the vaccine, participants developed neutralising antibodies at levels more than four times higher on average than the antibodies developed by people who had recovered from COVID-19. August 05, 2020 at 08:10AM https://ift.tt/2Dhr0c1
No comments:
Post a Comment